Brief: Alto Neuroscience Reports Positive Phase 2 Results for Alto-203, Identifies Biomarker
26/06/2025 12:38
June 26 (Reuters) - Alto Neuroscience Inc ANRO.N: ALTO NEUROSCIENCE IDENTIFIES BIOMARKER AND REPORTS POSITIVE PHARMACODYNAMIC RESULTS FROM EXPLORATORY PHASE 2 PROOF-OF-CONCEPT TRIAL OF ALTO-203 ALTO NEUROSCIENCE INC - ALTO-203 WELL TOLERATED WITH INSOMNIA AS MOST FREQUENT ADVERSE EVENT Source text: ID:nBw6JTfRZa Further company coverage: ANRO.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alto Neuroscience
See all newsBrief: Alto Neuroscience Promotes Nick Smith To President And Chief Financial Officer
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Brief: Alto Neuroscience - Proposed Resale Of Up To 6 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics
Brief: Alto Neuroscience Reports Topline Data From Phase 2 Proof-Of-Concept Study Of Alto-101 And Highlights Pipeline Advancements